Appendix B
Planning Committee Biographies
Brian R. Berridge (Co-Chair) is a senior GlaxoSmithKline (GSK) fellow and director and head of WW Animal Research Strategy in the Office of Animal Welfare, Ethics and Strategy at GSK. In that position he leads efforts to advance the scientific impact of animal and non-animal modeling in support of pharmaceutical development. He has held previous positions as a director of Regulatory & Discovery Pathology at GSK and principal research pathologist at Eli Lilly and Company. Dr. Berridge is an Oklahoma State University–trained veterinarian with residency and Ph.D. training from Texas A&M University. He is a diplomate of the American College of Veterinary Pathologists and holds an adjunct associate professor position in the Department of Population Health and Pathobiology at North Carolina State University. He additionally teaches cardiovascular toxicology at the University of North Carolina. He is a member of the executive board and board of trustees for the International Life Sciences Institute Health and Environmental Sciences Institute (HESI), where he also serves as treasurer and co-chairs the HESI Cardiac Safety Technical Committee and the Integrated CV Strategies Working Group. Dr. Berridge also chairs a CV Specialty Interest Group within the Society of Toxicologic Pathologists and a Microphysiological Systems Working Group within the IQ Consortium. He is a member of the Interagency Coordinating Committee on the Validation of Alternative Methods.
K.C. Kent Lloyd (Co-Chair) is a veterinarian and research scientist studying genome-wide mutagenesis in laboratory mice. Dr. Lloyd graduated with his bachelor of science degree from the University of California, San Diego,
with an emphasis in biology and biochemistry. He was accepted into the School of Veterinary Medicine at the University of California, Davis (UCD), from which he graduated in 1983 with his doctor of veterinary medicine degree. After a clinical internship at the New Bolton Center, University of Pennsylvania School of Veterinary Medicine, surgery residency at the UCD Veterinary Medical Teaching Hospital (VMTH), and brief appointment as a clinical faculty member in the VMTH, Dr. Lloyd matriculated in the School of Medicine at the University of California, Los Angeles (UCLA) where in 1992 he received his doctor of philosophy (Ph.D.) in physiology under the mentorship of Doctors John H. Walsh and Jared Diamond. After graduation, he joined the UCLA faculty as an Assistant Professor in the Department of Physiology where he established his National Institutes of Health (NIH)-funded research laboratory investigating the mechanisms of enterogastric reflexes. During the next 3 years, Dr. Lloyd served concurrently as a visiting scientist at the European Molecular Biology Laboratory in Heidelberg, Germany, where he engaged in pioneering work on conditional mutagenesis in the mouse. After earning a promotion to associate professor in 1996, Dr. Lloyd was recruited to the School of Veterinary Medicine at UCD as a tenured faculty member in the Department of Anatomy, Physiology, and Cell Biology and as a founding faculty member of the Center for Comparative Medicine. In 2001 he was promoted to full professor and was appointed as associate dean for research and graduate education. Dr. Lloyd assumed the role of director of the UCD Mouse Biology Program in 2002, taking over from founding director Dr. Stephen Barthold. In 2013 Dr. Lloyd was recruited to the UCD School of Medicine, where he is a professor in the Department of Surgery. Dr. Lloyd has an active NIH-funded research program that emphasizes the development and application of genetically altered mice for research that seeks to understand the biological functions of genes as well as the genetic basis of disease pathogenesis. He is an active participant in the education and training of undergraduate, graduate, and professional students and scholars. He also serves on many councils and committees at the school and campus level, in professional organizations (e.g., American Veterinary Medical Association), and at federal agencies (e.g., NIH). His current research is focused on in vivo precision modeling using next-generation molecular techniques for genome editing and manipulation in animals. He was recently named associate director of in vivo precision modeling at the UCD Center for Precision Health.
Cory Brayton is associate professor and director of Phenotyping and Pathology Core Facility at Johns Hopkins University, School of Medicine. She is a diplomate of the American College of Laboratory Animal Medicine and the American College of Veterinary Pathologists (ACVP). She served as president of ACVP in 2014, as well as on ACVP Council 2009-2012, and as
president elect, 2013. She received her D.V.M. from Cornell University and did postdoctoral research and pathology training in New York City at the Animal Medical Center, Cornell University, and The Rockefeller University. At The Rockefeller University (1989-1992), she became specifically interested in the pathology and characterization (phenotyping) of genetically engineered mice, and continued to pursue this interest at several institutions while heading the Facility for Comparative Studies at the Hospital for Special Surgery (1992-1998). At Baylor College of Medicine (1998-2004), she headed the Comparative Pathology Laboratory, and was responsible for health surveillance and diagnostic pathology for a diverse research population including more than 150,000 mice. She was also associate professor in pathology, associate director of the Center for Comparative Medicine, and interim attending veterinarian, and served on the Institutional Animal Care and Use Committee while pursuing research collaborations and teaching initiatives and developing national and international conferences on the characterization and pathology of genetically engineered mice. In 2004 she moved to Johns Hopkins University to develop a collaborative phenotyping core based in the Department of Molecular and Comparative Pathobiology, where veterinarian postdoctoral trainees and faculty investigators provide a unique comparative and translational research resource, in an institution with exceptional resources for multidisciplinary biomedical research. She has been on the ILAR council and co-editor-in-chief of the ILAR Journal since 2012.
Robert M. Califf is Donald F. Fortin, MD Professor of Cardiology at Duke University School of Medicine. He was the commissioner of food and drugs in 2016-2017 and deputy commissioner for medical products and tobacco from February 2015 until his appointment as commissioner in February 2016. Prior to joining the U.S. Food and Drug Administration (FDA), Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature. Dr. Califf became a member of the National Academy of Medicine (NAM) in 2016, one of the highest honors in the fields of health and medicine. Dr. Califf has served on numerous NAM committees, and he has served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board’s Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on
advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences, and the Council of the National Institute on Aging. He has led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative, a public–private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke’s Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory coordinating center and co-principal investigator of the Patient Centered Outcomes Research Institute Network. Dr. Califf is a graduate of Duke University School of Medicine. He completed a residency in internal medicine at the University of California, San Francisco, and a fellowship in cardiology at Duke.
Melissa Haendel co-leads the Monarch Initiative, which aims to provide open integrated access to model organism and human phenotype-genotype data for the purposes of disease hypothesis exploration. She also participates in the Open Research Information Framework, a community standard designed to collect and disseminate information about all types of scholarly products (such as code, material resources, etc.) and the contribution roles that scholars have in their generation. She also participates in development of interoperability standards, such as the new Phenopackets Phenotype Exchange Standard, is an Open Biomedical Ontologies Foundry coordinator, and is on the International Society for Biocuration executive board. Her research interests are in using semantic technologies to promote open and synthetic science through connections within biomedical data, and pushing toward a cultural shift to use of information science during the course of research for more effective science, publication of science, and collaborative science practices.
John P.A. Ioannidis is the C.F. Rehnborg Chair in Disease Prevention at Stanford University, professor of medicine and of health research and policy, at the School of Medicine; professor of statistics (by courtesy) at the School of Humanities and Sciences; co-director of the Meta-Research Innovation Center at Stanford; and director of the Ph.D. program in Epidemiology and Clinical Research. Dr. Ioannidis was born in New York City in 1965 and grew up in Athens, Greece. He was valedictorian at Athens College, received the National Award of the Greek Mathematical Society, graduated in the top rank of his medical school class from the University of Athens in 1990, and received a doctorate in biopathology from the same institution. Dr. Ioannidis trained at Harvard and Tufts in internal medicine and infectious diseases, then held positions at the National Institutes of Health (NIH), Johns Hopkins, and Tufts. Dr. Ioannidis has chaired the Department of Hygiene and Epidemiology at the University of Ioannina Medi-
cal School in 1999-2010 and has been adjunct faculty for Tufts University since 1996 (professor rank since 2002). He was director from 2008 to 2010 of the Center for Genetic Epidemiology and Modeling at Harvard School of Public Health and is adjunct professor of epidemiology at Harvard School of Public Health and visiting professor of epidemiology and biostatistics at Imperial College. Dr. Ioannidis is a member of the executive board of the Human Genome Epidemiology Network and senior advisor on knowledge integration at National Cancer Institute/NIH, and served as president for the Society for Research Synthesis Methodology. Dr. Ioannidis is an editorial board member of many leading journals (including PLoS Medicine, Lancet, Annals of Internal Medicine, JNCI, Science Translational Medicine, Clinical Chemistry, Molecular and Cellular Proteomics, AIDS, IJE, JCE, Clinical Trials, and PLoS ONE, among others) and as editor-in-chief of the European Journal of Clinical Investigation.